The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
Bharat Biotech expects to share further details of the trial results as additional data become available.
Subscribe To Our Newsletter & Stay Updated
